IP Library Granted Patent US 10,576,093
Granted Patent B2
US 10,576,093 · App. 15/963,648 · Granted Mar 3, 2020

Neuroprotection by mitochondria-targeted metformin

Inventors: Anumantha Kanthasamy (Ames, IA); Balaraman Kalyanaraman (Wauwatosa, WI)
Assignees: Iowa State University Research Foundation, Inc.; The Medical College of Wisconsin, Inc.
A61K31/662A61K31/4425
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,576,093
App. No.
15/963,648
Granted
Mar 3, 2020
Kind
B2
Abstract

The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.

Claims (21)

1. A method for providing a subject in need thereof with neuroprotection, comprising administering to said subject a neuroprotective composition which includes an effective amount of at least one modified metformin compound, wherein the modified metformin is selected from the group consisting of a mito-metformin, a mito-phenformin, a mito-PEG-metformin, a mito-cy-metformin or a pyrformin.

2. The method of claim 1 , wherein the subject suffers from a neurodegenerative disease.

3. The method of claim 2 , wherein the subject suffers from a neurodegenerative disease selected from the group consisting of Parkinson's disease, Alzheimer's disease and other related neurological diseases.

4. The method of claim 1 , wherein the subject is a mammal.

5. The method of claim 4 , wherein the mammal is a human.

6. The method of claim 1 , wherein the mito-metformin compound comprises the following structure:

wherein n is a positive integer between 1 and 11.

7. The method of claim 6 , wherein n is selected from the group consisting of two (2), three (3), four (4), six (6), seven (7), eight (8) and ten (10).

8. The method of claim 1 , wherein the mito-metformin compound comprises the following structure:

9. The method of claim 1 , wherein the mito-metformin compound comprises the following structure:

10. The method of claim 1 , wherein the mito-metformin compound comprises the following structure:

11. The method of claim 1 , wherein the mito-metformin compound comprises the following structure:

12. The method of claim 1 , wherein the mito-metformin compound comprises the following structure:

13. The method of claim 1 , wherein the administering to said subject the neuroprotective composition prevents, reduces or reverses neuronal cell death within the subject.

14. The method of claim 1 , wherein the method treats a neural injury in a subject having a neurodegenerative disease by administering an effective amount of the neuroprotection composition in order to treat the neural injury.

15. The method of claim 1 , wherein the neuroprotective composition is administered in an amount effective to prevent, reduce or treat at least one symptom in a subject suffering from a neurodegenerative disease.

16. The method of claim 15 , wherein the neurodegenerative disease is Parkinson's disease or Alzheimer's disease.

17. The method of claim 15 , wherein the modified metformin is a mito-metformin compound according to the following structure:

wherein n is a positive integer between 1 and 11.

18. The method of claim 17 , wherein n is selected from the group consisting of two (2), three (3), four (4), six (6), seven (7), eight (8) and ten (10).

19. The method of claim 15 , wherein the mito-metformin compound is selected from the group consisting of the following structures:

Assignments (6)
CONFIRMATORY LICENSE Recorded Oct 12, 2022
From: IOWA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061646/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: THE MEDICAL COLLEGE OF WISCONSIN, INC.
To: AIX-MARSEILLE UNIVERSITE
Reel/Frame 057034/0807 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 051595 FRAME 0359. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 21, 2020
From: KANTHASAMY, ANUMANTHA
To: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Reel/Frame 052740/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2020
From: KALYANARAMAN, BALARAMAN; KANTHASAMY, ANUMANTHA
To: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Reel/Frame 051595/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2020
From: KALYANARAMAN, BALARAMAN
To: THE MEDICAL COLLEGE OF WISCONSIN, INC.
Reel/Frame 051600/0725 →
CONFIRMATORY LICENSE Recorded Jul 16, 2018
From: IOWA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046545/0533 →
Continuity (3)
Continuation 15294083 · Oct 14, 2016
Provisional Application 62241818 · Oct 15, 2015
Related Publication 20190091245A1 · Mar 28, 2019